Compare Stocks: BLRX, IMMP, ANVS, and HOWL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.17 +12.0%	$1.67	$1.04 ▼ $5.50	$49.30M	1.24	858,506 shs	239,509 shs
BLRX BioLineRx	$2.55 +3.0%	$2.77	$2.15 ▼ $4.56	$12.25M	1.56	28,813 shs	1,688 shs
HOWL Werewolf Therapeutics	$0.97 +5.7%	$0.61	$0.27 ▼ $2.38	$47.39M	0.51	2.79 million shs	113,853 shs
IMMP Prima BioMed	$0.32 -1.8%	$0.38	$0.29 ▼ $3.53	$47.75M	2.21	5.39 million shs	16,052 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-4.44%	-12.46%	-38.92%	-39.09%	-54.93%
BLRX BioLineRx	-1.47%	-2.63%	-5.95%	-21.42%	-36.17%
HOWL Werewolf Therapeutics	-6.22%	-4.77%	+126.63%	+161.60%	-36.62%
IMMP Prima BioMed	-1.00%	-7.91%	-15.39%	-12.61%	-80.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.17 +12.0%	$1.67	$1.04 ▼ $5.50	$49.30M	1.24	858,506 shs	239,509 shs
BLRX BioLineRx	$2.55 +3.0%	$2.77	$2.15 ▼ $4.56	$12.25M	1.56	28,813 shs	1,688 shs
HOWL Werewolf Therapeutics	$0.97 +5.7%	$0.61	$0.27 ▼ $2.38	$47.39M	0.51	2.79 million shs	113,853 shs
IMMP Prima BioMed	$0.32 -1.8%	$0.38	$0.29 ▼ $3.53	$47.75M	2.21	5.39 million shs	16,052 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-4.44%	-12.46%	-38.92%	-39.09%	-54.93%
BLRX BioLineRx	-1.47%	-2.63%	-5.95%	-21.42%	-36.17%
HOWL Werewolf Therapeutics	-6.22%	-4.77%	+126.63%	+161.60%	-36.62%
IMMP Prima BioMed	-1.00%	-7.91%	-15.39%	-12.61%	-80.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.25	Hold	$12.00	930.04% Upside
BLRX BioLineRx	1.00	Sell	N/A	N/A
HOWL Werewolf Therapeutics	2.14	Hold	$4.00	311.95% Upside
IMMP Prima BioMed	2.40	Hold	$5.50	1,613.40% Upside

Current Analyst Ratings Breakdown

Latest BLRX, IMMP, ANVS, and HOWL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	IMMP Prima BioMed	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/10/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $7.00
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	BLRX BioLineRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	IMMP Prima BioMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/6/2026	ANVS Annovis Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/17/2026	IMMP Prima BioMed	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
BLRX BioLineRx	$1.18M	10.50	N/A	N/A	$5.36 per share	0.48
HOWL Werewolf Therapeutics	$1.88M	25.10	N/A	N/A	$0.51 per share	1.90
IMMP Prima BioMed	$16.40M	2.88	N/A	N/A	$0.28 per share	1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
BLRX BioLineRx	-$1.17M	-$1.69	N/A	N/A	N/A	-502.08%	-34.80%	-18.27%	11/23/2026 (Estimated)
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
IMMP Prima BioMed	-$53.82M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BLRX, IMMP, ANVS, and HOWL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/31/2026	Q2 2026	BLRX BioLineRx	-$0.15	-$0.77	-$0.62	-$0.77	$0.50 million	$0.29 million
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million
7/30/2026	Q4 2026	IMMP Prima BioMed	N/A	-$0.09	N/A	-$0.0850	N/A	$3.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	3.47	3.47
BLRX BioLineRx	0.13	1.20	1.04
HOWL Werewolf Therapeutics	N/A	2.91	2.91
IMMP Prima BioMed	N/A	5.69	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
BLRX BioLineRx	1.56%
HOWL Werewolf Therapeutics	64.84%
IMMP Prima BioMed	2.32%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
BLRX BioLineRx	1.10%
HOWL Werewolf Therapeutics	23.60%
IMMP Prima BioMed	3.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	7	42.68 million	33.80 million	Optionable
BLRX BioLineRx	40	4.85 million	4.80 million	Optionable
HOWL Werewolf Therapeutics	14	48.60 million	37.13 million	Optionable
IMMP Prima BioMed	2,021	147.37 million	142.85 million	Optionable

BLRX, IMMP, ANVS, and HOWL Headlines

Recent News About These Companies

Prima BioMed Stock Scheduled to Reverse Split on Monday, September 28th (NASDAQ:IMMP)

September 12, 2026 | americanbankingnews.com

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

July 13, 2026 | globenewswire.com

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

July 6, 2026 | prnewswire.com

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

July 2, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

July 2, 2026 | prnewswire.com

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

July 1, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

June 30, 2026 | globenewswire.com

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

June 30, 2026 | globenewswire.com

Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

June 29, 2026 | newsfilecorp.comN

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

June 29, 2026 | prnewswire.com

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

June 29, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

June 25, 2026 | prnewswire.com

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

June 25, 2026 | prnewswire.com

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

June 25, 2026 | prnewswire.com

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

June 24, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

June 23, 2026 | globenewswire.com

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

June 23, 2026 | globenewswire.com

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

June 22, 2026 | prnewswire.com

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

June 22, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

June 18, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, IMMP, ANVS, and HOWL Company Descriptions

Annovis Bio NYSE:ANVS

$1.16 +0.13 (+12.02%)

As of 10:34 AM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

BioLineRx NASDAQ:BLRX

$2.55 +0.07 (+2.98%)

As of 10:34 AM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Werewolf Therapeutics NASDAQ:HOWL

$0.97 +0.05 (+5.66%)

As of 10:34 AM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Prima BioMed NASDAQ:IMMP

$0.32 -0.01 (-1.83%)

As of 10:34 AM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLRX, IMMP, ANVS, and HOWL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLRX, IMMP, ANVS, and HOWL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLRX, IMMP, ANVS, and HOWL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, IMMP, ANVS, and HOWL Company Descriptions

Annovis Bio NYSE:ANVS

BioLineRx NASDAQ:BLRX

Werewolf Therapeutics NASDAQ:HOWL

Prima BioMed NASDAQ:IMMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLRX, IMMP, ANVS, and HOWL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLRX, IMMP, ANVS, and HOWL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLRX, IMMP, ANVS, and HOWL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, IMMP, ANVS, and HOWL Company Descriptions

Annovis Bio NYSE:ANVS

BioLineRx NASDAQ:BLRX

Werewolf Therapeutics NASDAQ:HOWL

Prima BioMed NASDAQ:IMMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools